Adipocyte Reprogramming via HB-EGF and ADAM12S
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively addressing obesity and related metabolic diseases, as they fail to provide a sustainable solution for weight management and metabolic health improvement.
Innovation Solution
The co-expression of heparin-binding EGF-like growth factor (HB-EGF) and A Disintegrin and Metalloproteinase (ADAM) 12S is used to reprogram cells into brown adipose tissue (BAT)-like cells, which exhibit increased mitochondria, lipid droplet accumulation, and enhanced metabolic activity, thereby mimicking the properties of BAT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional weight management methods are used, then treatment simplicity is maintained, but effectiveness in addressing obesity and metabolic diseases is insufficient
Solution Approach 1:
The invention changes the fundamental parameter of cell type by reprogramming white adipocytes into brown adipocytes through genetic modification. This transforms the metabolic function of adipose tissue from energy storage to energy expenditure, directly addressing obesity and metabolic diseases with a targeted biological intervention that overcomes the limitations of conventional approaches.
2Reliability
If white adipose tissue is present, then energy storage function is maintained, but metabolic disease risk increases
Solution Approach 1:
The invention changes the phenotypic parameter of adipocytes from white to brown through overexpression of specific genes (PRDM16, UCP-1, PGC-1α). This transforms the functional parameter of the tissue from energy storage to thermogenic energy expenditure, reducing metabolic disease risk while maintaining adipose tissue presence.
Solution Approach 2:
The invention converts the harmful effect of excess white adipose tissue (energy storage leading to obesity) into a beneficial effect by reprogramming it to function as brown adipose tissue (energy expenditure through thermogenesis). This transforms the pathological adipose tissue into a therapeutic asset for treating obesity and metabolic diseases.
3Reliability
If brown adipose tissue is increased through reprogramming, then metabolic disease treatment effectiveness is improved, but cellular differentiation control becomes more challenging
Solution Approach 1:
The invention performs preliminary action by introducing genetic modifications (overexpression of PRDM16, UCP-1, or PGC-1α) into white adipocytes before functional reprogramming occurs. This pre-establishes the molecular machinery needed for brown adipocyte differentiation and thermogenesis, making the reprogramming process more可控 and effective.
Solution Approach 2:
The invention uses intermediary molecules (transcription factors PRDM16, UCP-1, and PGC-1α) as mediators to facilitate the transformation from white to brown adipocytes. These intermediaries act as molecular bridges that guide the cellular reprogramming process and maintain the new brown adipocyte phenotype.
Data Source
AI summary
Obesity and related conditions and diseases pose ever increasing issues for the developed world. There is a need for interventions that can treat/prevent the underlying causes of e.g., diabetes and obesity. Accordingly compositions and methods for altering at least one expression level related to cellular metabolism are disclosed herein.